Legend Capital has returned to invest in the metabolic and immunological disease-focused biotechnology developer, having backed its series A round two years ago.
China-based metabolic disease therapy developer Sciwind Biosciences has raised $37m in series B funding from investors including Legend Capital, the venture capital firm spun out of conglomerate Legend Holdings. Life sciences-focused investment firm Lyfe Capital led the round, investing with VC firm Haibang Venture Capital, which was identified as an existing backer. Founded in 2017,…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
